Kingsoft Cloud Holdings Limited vs Viatris Inc — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 7.4× Kingsoft Cloud Holdings Limited's market cap, and Viatris Inc pays a 2.75% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Viatris Inc for 57 Days on average.
| KC | VTRS | |
|---|---|---|
Market Cap | $2.71B | $20.03B |
Volume | 1,993,765 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $18.21 | $18.27 |
52-Week Low | $8.58 | $9.74 |
Typical Hold Time | 12 Days | 57 Days |
Enterprise Value | $3.03B | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $9.26, up 0.33% with bearish technical indicators but strong analyst support. The company shows improving fundamentals with Q2 2026 revenue growth of 30.8% year-over-year and three consecutive earnings beats. Despite negative net margins, gross margins improved significantly to 15.05% as AI cloud services drive growth. Cash flow from operations reached $3.8 billion in 2025, though 2026 projections show negative net cash flow.
KC presents a compelling turnaround story with AI-driven growth potential, trading at attractive valuation multiples (P/S: 1.58, EV/EBITDA: 2,203). However, persistent losses and negative cash flow projections for 2026 pose significant execution risks. The 70% analyst buy rating and 60% upside potential must be weighed against the bearish technical picture and competitive cloud market dynamics.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →